Phase II study of lapatinib plus capecitabine for the HER2 overexpressing metastatic breast cancer patients pretreated with oral-FU agents.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 08 Sep 2011 Planned end date changed from 1 Aug 2011 to 1 Aug 2012 as reported by University Hospital Medical Information Network - Japan.
- 08 Sep 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 11 Sep 2009 New trial record